TIDMMTPH

RNS Number : 0952E

Midatech Pharma PLC

09 March 2022

9 March 2022

Midatech Pharma PLC

("Midatech" or the "Company")

Midatech announces R&D collaboration with Janssen on a second molecule

Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce an extension of its existing R&D collaboration with Janssen Pharmaceutica NV (Janssen) originally announced on 21 July 2020.

On 17 June 2021 the Company announced that, using its Q-Sphera technology, it had successfully encapsulated a proprietary Janssen experimental large molecule medicine and importantly preserved its functional integrity. The Company believes no other commercial or academic organisation has been able to successfully deliver any such experimental medicine over extended periods using methods capable of commercial scaling.

Following the initial programme (MTX213), the collaboration has been extended to include another large molecule to the research performed by Midatech for Janssen. As with the MTX213 molecule, the work will concentrate on maximizing drug loading and optimizing in vitro duration of release for this undisclosed Janssen experimental molecule using the Midatech's Q-Sphera technology.

Dmitry Zamoryakhin, Chief Scientific Officer of Midatech, said:

"We look forward to working with Janssen and the application of our technology specific to this new API."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

 
  For more information, please contact: Midatech Pharma PLC 
    Stephen Stamp, CEO, CFO 
     Dmitry Zamoryakhin, CSO 
    Tel: +44 (0)29 2048 0180 
    www.midatechpharma.com 
 
    Strand Hanson Limited (Nominated and Financial Adviser) 
    James Dance / Matthew Chandler / Rob Patrick 
    Tel: +44 (0)20 7409 3494 
 
    Turner Pope Investments (TPI) Limited (Broker) 
    Andrew Thacker / James Pope (Corporate Broking) 
     Tel: +44(0)20 3657 0050 
    IFC Advisory Limited (Financial PR and UK Investor Relations) 
    Tim Metcalfe / Graham Herring 
    Tel: +44 (0)20 3934 6630 
    Email: midatech@investor-focus.co.uk 
 
    Edison Group (US Investor Relations) 
     Alyssa Factor 
     Tel: +1 (860) 573 9637 
     Email: afactor@edisongroup.com 
        About Midatech Pharma PLC 
         Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: 
         MTP) is a drug delivery technology company focused on improving 
         the bio-delivery and bio-distribution of medicines. The Company 
         combines approved and development medications with its proprietary 
         and innovative drug delivery technologies to provide compelling 
         products that have the potential to powerfully impact the 
         lives of patients. 
         The Company has developed three in-house technology platforms, 
         each with its own unique mechanism to improve delivery of 
         medications to sites of disease. All of the Company's technologies 
         have successfully entered human use in the clinic, providing 
         important validation of the potential for each platform: 
          *    Q-Sphera(TM) platform: a disruptive micro-technology 
               used for sustained release to prolong and control the 
               release of therapeutics over an extended period of 
               time (from weeks to months). 
 
 
          *    MidaSolve(TM) platform: an innovative nanotechnology 
               used to dissolve insoluble drugs so that they can be 
               administered in liquid form directly and locally into 
               tumours. 
 
 
          *    MidaCore(TM) platform: a leading-edge nanotechnology 
               used for targeting medications to sites of disease. 
 
 
         The platform nature of the technologies offers the potential 
         to develop multiple drug assets rather than being reliant 
         on a limited number of programmes. Midatech's technologies 
         are supported by 36 patent families including 120 granted 
         patents and an additional 70 patent applications. Midatech's 
         headquarters and R&D facility is in Cardiff, UK. For more 
         information please visit www.midatechpharma.com 
 Forward-Looking Statements 
  Certain statements in this press release may constitute "forward-looking 
  statements" within the meaning of legislation in the United 
  Kingdom and/or United States Private Securities Litigation 
  Reform Act. All statements contained in this press release 
  that do not relate to matters of historical fact should be 
  considered forward-looking statements, including, but not 
  limited to, any payments that may be received, the success 
  of the research collaboration in developing novel products, 
  the strategic review and formal sale process. 
  Reference should be made to those documents that Midatech 
  shall file from time to time or announcements that may be 
  made by Midatech in accordance with the London Stock Exchange 
  AIM Rules for Companies ("AIM Rules"), the Disclosure and 
  Transparency Rules ("DTRs") and the rules and regulations 
  promulgated by the US Securities and Exchange Commission, 
  which contains and identifies other important factors that 
  could cause actual results to differ materially from those 
  contained in any projections or forward-looking statements. 
  These forward-looking statements speak only as of the date 
  of this announcement. All subsequent written and oral forward-looking 
  statements by or concerning Midatech are expressly qualified 
  in their entirety by the cautionary statements above. Except 
  as may be required under the AIM Rules or the DTRs or by relevant 
  law in the United Kingdom or the United States, Midatech does 
  not undertake any obligation to publicly update or revise 
  any forward-looking statements because of new information, 
  future events or otherwise arising.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUPUWWWUPPGMR

(END) Dow Jones Newswires

March 09, 2022 02:00 ET (07:00 GMT)

Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Midatech Pharma Charts.
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Midatech Pharma Charts.